Form 4: Pulse Biosciences CTO Sells Shares Under 10b5-1 Plan

Pulse Biosciences' Chief Technology Officer, Darrin Uecker, reported exercising stock options and selling common stock totaling 45,000 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences, Inc. (PLSE), reported multiple transactions involving the company's common stock.
• On September 16, 2025, Uecker exercised options to acquire 25,000 shares at an exercise price of $4.00 per share and subsequently sold 25,000 shares at a weighted average price of $16.28 per share.
• On September 17, 2025, Uecker exercised options to acquire 20,000 shares at an exercise price of $4.00 per share and sold 20,000 shares at a weighted average price of $16.21 per share.
• Additional option exercises on September 17, 2025, included 61,534 shares and 100,000 shares, both at an exercise price of $4.00 per share, which were not immediately sold.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Uecker on June 12, 2025.
• Following these transactions, Uecker's direct beneficial ownership of common stock increased to 284,406 shares after the final option exercises.

Sentiment

Score: 5

Explanation: The transactions are part of a pre-arranged 10b5-1 plan, indicating a planned liquidity event rather than a reactive sale based on new information. While the executive is taking profits, this does not necessarily signal a change in the company's fundamental outlook, making the sentiment neutral for the company.

Positives

• The exercise of stock options at a price of $4.00 per share and subsequent sale at weighted average prices of $16.28 and $16.21 per share indicates a significant in-the-money value for the options, reflecting past stock price appreciation.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned liquidity event rather than a reactive sale based on new, non-public information.

Negatives

• The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some investors as a lack of conviction in the company's near-term growth prospects, although this is mitigated by the pre-planned nature.

Risks

• No specific risks are detailed in this Form 4 filing. However, a general risk associated with insider selling is the potential for negative market perception, which could put downward pressure on the stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to Pulse Biosciences and does not provide broader industry trends or competitive analysis. However, insider transactions are a common occurrence across all industries, particularly in high-growth sectors like biotechnology where executive compensation often includes significant equity components.

Stakeholder Impact

• Shareholders: May interpret the insider selling, even if planned, as a signal, potentially leading to minor short-term price fluctuations. However, the pre-planned nature mitigates the negative signaling effect.
• Management: The Chief Technology Officer is realizing value from long-held options, which is a normal part of executive compensation and wealth management.

Key Dates

Keywords

Pulse Biosciences, PLSE, Insider Trading, Form 4, Darrin Uecker, Stock Options, 10b5-1 Plan, Executive Compensation, Biotechnology